Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SAR447971 · KT-485

Small molecule

Phase 1 Most advanced trial
1 Registered trials

What is SAR447971?

SAR447971 (also known as KT-485) is an oral tablet formulation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KT-485
Drug type
Small molecule
Therapy area
Dermatology
In trials of
KYMR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07629336 Phase 1 Hidradenitis Recruiting KYMR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy VolunteersHidradenitis

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.